Histamine H3 receptor antagonists in the treatment of obesity

Handbook of Obesity: Clinical Applications, Third Edition

Volumn , Issue , 2008, Pages 395-404

  Rimvall, Karin ^a   Hohlweg, Rolf ^b   MalmlóF, Kjell ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b NOVO NORDISK A S   (Denmark)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959944932     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (69)

1. Reiner PB, Heimrich B, Keller F, et al. Organotypic culture of central histamine neurons. Brain Res 1988; 442:166-170.
2. Panula P, Yang HYT, Costa E. Histamine-containing neurons in the rat hypothalamus. Proc Natl Acad Sci U S A 1984; 81:2572-2576.
3. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003; 4:121-130.
4. Panula P, Pirvola U, Auvinen S, et al. Histamineimmunoreactive nerve fibers in the rat brain. Neuroscience 1989; 28:585-610.
5. Hough LB. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 2001; 59:415-419.
6. Yamashita M, Fukui H, Sugama K, et al. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc Natl Acad Sci U S A 1991; 88:11515-11519.
7. Palacios JM, Wamsley JK, Kuhar MJ. The distribution of histamine H1-receptors in the rat brain: an autoradiographic study. Neuroscience 1981; 6:15-37.
8. Hancock AA, Fox GB. Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 2004; 13(10):1237-1248.
9. Gantz I, Munzert G, Tashiro T, et al. Molecular cloning of the human histamine H2 receptor. Biochem Biophys Res Commun 1991; 178:1386-1392.
10. Hatton GI, Yang QZ. Ionotropic histamine receptors and H-2 receptors modulate supraoptic oxytocin neuronal excitability and dye coupling. J Neurosci 2001; 21:2974-2982.
11. Karlstedt K, Senkas A, Ahman M, et al. Regional expression of the histamine H(2) receptor in adult and developing rat brain. Neuroscience 2001; 102:201-208.
12. Honrubia MA, Vilaro MT, Palacios JM, et al. Distribution of the histamine H2 receptor in monkey brain and its mRNA localization in monkey and human brain. Synapse (New York) 2000; 38:343-354.
13. Arrang J, Garbarg M, Schwartz J. Auto inhibition of brain histamine release mediated by a novel class of H-3 of histamine receptor. Nature (London) 1983; 302:832-837.
14. Arrang JM, Garbarg M, Schwartz JC. Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors. Neuroscience 1987; 23:149-157.
15. Schlicker E, Malinowska B, Kathmann M, et al. Modulation of neurotransmitter release via histamine h-3 heteroreceptors. Fund Clin Pharm 1994; 8:128-137.
16. Lovenberg TW, Roland BL, Wilson SJ et al. Cloning and functional expression of the human histamine H-3 receptor. Mol Pharmacol 1999; 55:1101-1107.
17. Lovenberg TW, Pyati J, Chang H, et al. Cloning of rat histamine H-3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 2000; 293:771-778.
18. Hancock AA, Esbenshade TA, Krueger KM, et al. Genetic and pharmacological aspects of histamine H-3 receptor heterogeneity. Life Sci 2003; 73:3043-3072.
19. Varty LM, Gustafson E, Laverty M, et al. Activation of histamine H-3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur J Pharmacol 2004; 484:83-89.
20. Silver RB, Mackins CJ, Smith NCE, et al. Coupling of histamine H-3 receptors to neuronal Naþ/Hþ exchange: a novel protective mechanism in myocardial ischemia. Proc Natl Acad Sci U S A 2001; 98:2855-2859.
21. Pillot C, Heron A, Cochois V, et al. A detailed mapping of the histamine H-3 receptor and its gene transcripts in rat brain. Neuroscience 2002; 114:173-193.
22. Oda T, Morikawa N, Saito Y, et al. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000; 275(47):36781-36786.
23. Zhu Y, Michalovich D, Wu HL, et al. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 2001; 59:434-441.
24. Malmlöf K, Hohlweg R, Rimvall K. Targeting of the central histaminergic system for treatment of obesity and associated metabolic disorders. Drug Dev Res 2006; 67(8):651-665.
25. Hancock AA, Brune ME. Assessment of pharmacology and potential anti-obesity properties of H-3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 2005; 14(3):223-241.
26. Masaki T, Yoshimatsu H. The hypothalamic H-1 receptor:a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharm Sci 2006; 27(5):279-284.
27. Clineschmidt BV, Lotti VJ. Histamine: intraventricular injection suppresses ingestive behavior of the cat. Arch Int Pharmacodyn Ther 1973; 206:288-298.
28. Lecklin A, Tuomisto L. The blockade of H1 receptors attenuates the suppression of feeding and diuresis induced by inhibition of histamine catabolism. Pharmacol Biochem Behav 1998; 59:753-758.
29. Orthen-Gambill N. Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharmacol Biochem Behav 1988; 31:81-86.
30. Vaziri P, Dang K, Anderson GH. Evidence for histamine involvement in the effect of histidine loads on food and water intake in rats. J Nutr 1997; 127:1519-1526.
31. Lecklin A, Tuomisto L, Macdonald E. Metoprine, an inhibitor of histamine N-methyltransferase but no catechol-O-methyltransferase, suppresses feeding in sated and in food deprived rats. Methods Find Exp Clin Pharmacol 1995; 17:47-52.
32. Bjenning C, Juul A-G, Lange KZ, et al. Peripherally administered ciproxifan elevates hypothalamic histamine levels and potently reduces food intake in the Sprague Dawley rat. In: Watanabe T, Timmerman H, Yanai K, eds. Histamine Research in the New Millennium. Amsterdam:Elsevier, 2001:449-450.
33. Malmlöf K, Zaragoza F, Golozoubova V, et al. Influence of a selective histamine H-3 receptor antagonist on hypothalamic neural activity, food intake and body weight. Int J Obes 2005; 29(12):1402-1412.
34. Malmlö f K, Golozoubova V, Peschke B, et al. Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides. Obesity 2006; 14:2154-2162.
35. Lecklin A, Etuseppala P, Stark H, et al. Effects of intracerebroventricularly infused histamine and selective h-1, h-2 and h-3 agonists on food and water-intake and urine flow in wistar rats. Brain Res 1998; 793:279-288.
36. Sakata T, Ookuma K, Fukagawa K, et al. Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res 1988; 441:403-407.
37. Morimoto T, Yamamoto Y, Mobarakeh JI et al. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav 1999; 67:679-683.
38. Ookuma K, Sakata T, Fujimoto K. Evidence for feeding elicited through antihistaminergic effects of tricyclic antidepressants in the rat hypothalamus. Psychopharmacology 1990; 101:481-485.
39. Tuomisto L, Lozeva V, Valjakka A, et al. Modifying effects of histamine on circadian rhythms and neuronal excitability. Behav Brain Res 2001; 124(2):129-135.
40. Malmlöf K, Hastrup S, Wulff BS, et al. Antagonistic targeting of the histamine H3 receptor decreases caloric intake in higher mammalian species. Biochem Pharmacol 2007; 73:1237-1242.
41. Hancock AA, Bennani YL, Bush EN, et al. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. Eur J Pharmacol 2004; 487:183-197.
42. Hancock AA. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Biochem Pharmacol 2006; 71(8):1103-1113.
43. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22(9):1462-1470.
44. Yasuda T, Masaki T, Chiba S, et al. L-Histidine stimulates sympathetic nerve activity to brown adipose tissue in rats. Neurosci Lett 2004; 362:71-74.
45. Yasuda T, Masaki T, Sakata T, et al. Hypothalamic neuronal histamine regulates sympathetic nerve activity and expression of uncoupling protein 1 mRNA in brown adipose tissue in rats. Neuroscience 2004; 125(3):535-540.
46. Tsuda K, Yoshimatsu H, Niijima A, et al. Hypothalamic histamine neurons activate lipolysis in rat adipose tissue. Exp Biol Med 2002; 227(3):208-213.
47. Berken GH, Weinstein DO, Stern WC. Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord 1984; 7:133-138.
48. Baptista T, Zarate J, Joober R, et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004; 5:279-299.
49. Kraus T, Zimmermann U, Schuld A, et al. On the pathophysiology of weight regulation during treatment with psychotropic drugs. Forschritte Neurol Psychiatr 2001; 69:116-137.
50. Van Ganse E, Kaufman L, Derde MP, et al. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997; 10:2216-2224.
51. Horak F, Stubner UP. Comparative tolerability of second generation antihistamines. Drug Safety 1999; 20:385-401.
52. http://www.media.corporate-ir.net/media_files/IROL/10/101911/Lehman_2007_v3_FINAL. pdf.
53. Reda TK, Geliebter A, Pi-Sunyer FX. Amylin, food intake, and obesity. Obes Res 2002; 10:1087-1091.
54. Rushing PA, Hagan MM, Seeley RJ, et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 2001; 142:5035-5038.
55. Roth JD, Hughes H, Kendall E, et al. Antiobesity effects of the beta-cell hormone amylin in diet- induced obese rats:effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 2006; 147(12):5855-5864.
56. Mollet A, Lutz TA, Meier S, et al. Histamine H-1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1442-R1448.
57. Mollet A, Meier S, Riediger T, et al. Histamine H1 receptors in the ventromedial hypothalamus mediate the anorectic action of the pancreatic hormone amylin. Peptides 2003; 24:155-158.
58. Lutz TA, Del Prete E, Walzer B, et al. The histaminergic, but not the serotoninergic, system mediates amylin’s anorectic effect. Peptides 1996; 17:1317-1322.
59. D’Este L, Wimalawansa SJ, Renda TG. Distribution of amylin-immunoreactive neurons in the monkey hypothalamus and their relationships with the histaminergic system. Arch Histol Cytol 2001; 64:295-303.
60. Sander LE, Lorentz A, Sellge G, et al. Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut 2006; 55(4):498-504.
61. Imamura M, Seyedi N, Lander HM, et al. Functional identification of histamine H3-receptors in the human heart. Circ Res 1995; 77(1):206-210.
62. Mackins CJ, Levi R. Therapeutic potential of H(3)-receptor agonists in myocardial infarction. Expert Opin Investig Drugs 2000; 9(11):2537-2542.
63. Witkin JM, Nelson DL. Selective histamine H-3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004; 103:1-20.
64. Passani MB, Lin JS, Hancock A, et al. The histamine H-3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharm Sci 2004; 25(12):618-625.
65. Barbier AJ, Berridge C, Dugovic C, et al. Acute wakepromoting actions of JNJ-5207852, a novel, diamine-based H-3 antagonist. Br J Pharmacol 2004; 143(5):649-661.
66. Passani MB, Cangioli L, Baldi E, et al. Histamine H-3 receptor-mediated impairment of contextual fear conditioning and in-vivo inhibition of cholinergic transmission in the rat basolateral amygdala. Eur J Neurosci 2001; 14:1522-1532.
67. Yuzurihara M, Ikarashi Y, Ishige A, et al. Effects of drugs acting as histamine releasers or histamine receptor blockers on an experimental anxiety model in mice. Pharmacol Biochem Behav 2000; 67(1):145-150.
68. Bongers G, Leurs R, Robertson J, et al. Role of H-3- receptor-mediated signaling in anxiety and cognition in wild-type and Apoe(_=_) mice. Neuropsychopharmacology 2004; 29:441-449.
69. Perez-Garcia C, Morales L, Cano MV, et al. Effects of histamine H-3 receptor ligands in experimental models of anxiety and depression. Psychopharmacology 1999; 142:215-220.